The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Brian I. Rini; Dena Battle; Robert A. Figlin; Daniel J. George; Hans Hammers; Tom Hutson; Eric Jonasch; Richard W. Joseph; David F. McDermott; Robert J. Motzer; Sumanta K. Pal; Allan J. Pantuck; David I. Quinn; Virginia Seery; Martin H. Voss; Christopher G. Wood; Laura S. Wood; Michael B. Atkins

doi:10.1186/s40425-019-0813-8

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Research output: Contribution to journal › Article › peer-review

175 Scopus citations

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- A nd poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Original language	English (US)
Article number	354
Journal	Journal for ImmunoTherapy of Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0813-8
State	Published - Dec 20 2019

Keywords

Guidelines
Immune checkpoint inhibitor (ICI)
Immunotherapy
Kidney cancer
Renal cell carcinoma (RCC)

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1186/s40425-019-0813-8

Cite this

Rini, B. I., Battle, D., Figlin, R. A., George, D. J., Hammers, H., Hutson, T., Jonasch, E., Joseph, R. W., McDermott, D. F., Motzer, R. J., Pal, S. K., Pantuck, A. J., Quinn, D. I., Seery, V., Voss, M. H., Wood, C. G., Wood, L. S., & Atkins, M. B. (2019). The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). Journal for ImmunoTherapy of Cancer, 7(1), Article 354. https://doi.org/10.1186/s40425-019-0813-8

Rini, BI, Battle, D, Figlin, RA, George, DJ, Hammers, H, Hutson, T, Jonasch, E, Joseph, RW, McDermott, DF, Motzer, RJ, Pal, SK, Pantuck, AJ, Quinn, DI, Seery, V, Voss, MH, Wood, CG, Wood, LS & Atkins, MB 2019, 'The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 354. https://doi.org/10.1186/s40425-019-0813-8

@article{b2982bd8c23f481f8fdc91a562b3c61c,

title = "The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)",

abstract = "The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- A nd poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.",

keywords = "Guidelines, Immune checkpoint inhibitor (ICI), Immunotherapy, Kidney cancer, Renal cell carcinoma (RCC)",

author = "Rini, {Brian I.} and Dena Battle and Figlin, {Robert A.} and George, {Daniel J.} and Hans Hammers and Tom Hutson and Eric Jonasch and Joseph, {Richard W.} and McDermott, {David F.} and Motzer, {Robert J.} and Pal, {Sumanta K.} and Pantuck, {Allan J.} and Quinn, {David I.} and Virginia Seery and Voss, {Martin H.} and Wood, {Christopher G.} and Wood, {Laura S.} and Atkins, {Michael B.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = dec,

day = "20",

doi = "10.1186/s40425-019-0813-8",

language = "English (US)",

volume = "7",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

AU - Rini, Brian I.

AU - Battle, Dena

AU - Figlin, Robert A.

AU - George, Daniel J.

AU - Hammers, Hans

AU - Hutson, Tom

AU - Jonasch, Eric

AU - Joseph, Richard W.

AU - McDermott, David F.

AU - Motzer, Robert J.

AU - Pal, Sumanta K.

AU - Pantuck, Allan J.

AU - Quinn, David I.

AU - Seery, Virginia

AU - Voss, Martin H.

AU - Wood, Christopher G.

AU - Wood, Laura S.

AU - Atkins, Michael B.

PY - 2019/12/20

Y1 - 2019/12/20

N2 - The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- A nd poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

AB - The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- A nd poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

KW - Guidelines

KW - Immune checkpoint inhibitor (ICI)

KW - Immunotherapy

KW - Kidney cancer

KW - Renal cell carcinoma (RCC)

UR - http://www.scopus.com/inward/record.url?scp=85077030435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077030435&partnerID=8YFLogxK

U2 - 10.1186/s40425-019-0813-8

DO - 10.1186/s40425-019-0813-8

M3 - Article

C2 - 31856918

AN - SCOPUS:85077030435

SN - 2051-1426

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 1

M1 - 354

ER -

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this